Gamco Investors INC. ET AL Acquires 42,100 Shares of GRAIL, Inc. $GRAL

Gamco Investors INC. ET AL lifted its holdings in GRAIL, Inc. (NASDAQ:GRAL) by 170.7% in the 1st quarter, Holdings Channel.com reports. The firm owned 66,758 shares of the company’s stock after buying an additional 42,100 shares during the quarter. Gamco Investors INC. ET AL’s holdings in GRAIL were worth $3,450,000 as of its most recent SEC filing.

Other large investors have also bought and sold shares of the company. Farallon Capital Management LLC raised its holdings in GRAIL by 73.7% during the 4th quarter. Farallon Capital Management LLC now owns 2,342,684 shares of the company’s stock worth $200,510,000 after buying an additional 993,684 shares during the period. Baker BROS. Advisors LP boosted its holdings in shares of GRAIL by 27.9% in the fourth quarter. Baker BROS. Advisors LP now owns 2,085,333 shares of the company’s stock valued at $178,484,000 after buying an additional 455,208 shares during the period. Vanguard Group Inc. increased its position in shares of GRAIL by 9.0% during the fourth quarter. Vanguard Group Inc. now owns 1,980,783 shares of the company’s stock worth $169,535,000 after acquiring an additional 163,790 shares in the last quarter. State Street Corp increased its position in shares of GRAIL by 38.8% during the fourth quarter. State Street Corp now owns 1,827,523 shares of the company’s stock worth $156,418,000 after acquiring an additional 510,546 shares in the last quarter. Finally, Morgan Stanley raised its holdings in shares of GRAIL by 63.8% during the fourth quarter. Morgan Stanley now owns 1,511,687 shares of the company’s stock worth $129,385,000 after acquiring an additional 588,647 shares during the period.

GRAIL Stock Down 1.6%

NASDAQ GRAL opened at $66.77 on Tuesday. The firm’s 50 day moving average is $66.67 and its 200-day moving average is $68.31. The company has a market capitalization of $2.87 billion, a PE ratio of -6.44 and a beta of 3.22. GRAIL, Inc. has a 12-month low of $29.95 and a 12-month high of $118.84.

GRAIL (NASDAQ:GRAL) last announced its earnings results on Tuesday, May 5th. The company reported ($2.29) EPS for the quarter, topping the consensus estimate of ($2.76) by $0.47. The business had revenue of $40.78 million during the quarter, compared to analysts’ expectations of $39.16 million. GRAIL had a negative net margin of 253.22% and a negative return on equity of 16.42%. As a group, sell-side analysts expect that GRAIL, Inc. will post -10.91 EPS for the current year.

Key GRAIL News

Here are the key news stories impacting GRAIL this week:

• Neutral Sentiment: Several law firms reminded investors that August 4, 2026 is the deadline to seek appointment as lead plaintiff in a proposed class action covering investors who purchased GRAIL securities from May 13, 2025, through February 19, 2026. These notices are procedural and do not establish that GRAIL or its executives violated securities laws. GRAL Shareholder Alert: August 4, 2026 Lead Plaintiff Deadline
• Negative Sentiment: Bronstein, Gewirtz & Grossman announced that a securities class action has been filed against GRAIL, Inc. (GRAL) and certain officers, seeking damages for alleged federal securities-law violations during the stated class period. The allegations add potential litigation costs, reputational risk and uncertainty for shareholders. GRAIL Investor Class Action Announcement
• Negative Sentiment: Additional firms, including Hagens Berman, Faruqi & Faruqi, Bleichmar Fonti & Auld, DJS Law Group and Robbins Geller, promoted the same or related litigation after the reported NHS-Galleri trial setback and sharp stock decline. The volume of announcements reinforces near-term legal overhang and may weigh on investor sentiment, although the notices largely repeat existing allegations rather than disclose new operating results. GRAIL Lawsuit Notice After Stock Drop

Analyst Upgrades and Downgrades

Several research firms recently commented on GRAL. Robert W. Baird set a $70.00 price objective on shares of GRAIL in a research report on Wednesday, May 6th. Piper Sandler lifted their price target on GRAIL from $54.00 to $56.00 and gave the company a “neutral” rating in a research note on Wednesday, May 6th. The Goldman Sachs Group initiated coverage on GRAIL in a report on Friday, June 5th. They issued a “neutral” rating and a $60.00 price target on the stock. Wall Street Zen raised GRAIL from a “sell” rating to a “hold” rating in a research report on Saturday, May 9th. Finally, TD Cowen reaffirmed a “buy” rating on shares of GRAIL in a research report on Wednesday, July 15th. Four analysts have rated the stock with a Buy rating, five have assigned a Hold rating and one has given a Sell rating to the company. Based on data from MarketBeat.com, the company currently has an average rating of “Hold” and an average price target of $67.78.

Insider Buying and Selling

In other GRAIL news, insider Andrew John Partridge sold 1,491 shares of the business’s stock in a transaction dated Thursday, June 4th. The shares were sold at an average price of $61.08, for a total transaction of $91,070.28. Following the sale, the insider directly owned 163,738 shares of the company’s stock, valued at $10,001,117.04. The trade was a 0.90% decrease in their position. The sale was disclosed in a filing with the SEC, which is available through this link. 1.83% of the stock is owned by company insiders.

GRAIL Company Profile

GRAIL, Inc (NASDAQ: GRAL) is a biotechnology company dedicated to the early detection of cancer through a multi-cancer blood test. Leveraging advances in next-generation sequencing, cell-free DNA (cfDNA) analysis and machine learning, GRAIL has developed the Galleri™ test, which aims to identify more than 50 types of cancer at their earliest stages. The company’s platform analyzes methylation patterns in circulating tumor DNA to pinpoint tumor presence and tissue of origin, enabling physicians to pursue timely diagnostic follow-up.

Founded in 2016 as a spin-out from Illumina, GRAIL established its headquarters in Menlo Park, California, with additional research and operations centers in the United Kingdom.